Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR

NCT03796104 | Unknown

• 1 other identifier: 18-333
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to determine if delta-haemolysin production deficiency of Staphylococcus aureus is a marker in favour of chronic infections on implants

Conditions

Bone and Joint Infection; Staphylococcus Aureus

Keywords

Bone and Joint Infection; Staphylococcus Aureus; chronic infection

Outcome Measures

Primary Outcomes (1)

• Rate of infection with or witout delta-haemolysin in Staphylococcus Aureus

  patients, profile of the bacterium, medical and chirurgical treatment, rate. comparison between the 2 groups

  Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption

Secondary Outcomes (1)

• Rate of Treatment Failure

  Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption

Study Arms (2)

Deficiency of delta-hemolysine

Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency

Other: Delta-haemolysin

Presence of delta-hemolysine

Implant infected by Staphylococcus aureus with delta-haemolysin Production

Other: Delta-haemolysin

Interventions

Delta-haemolysin OTHER

comparison of groups having infection with S. aureus with and without delta-haemolysin Production

Deficiency of delta-hemolysine; Presence of delta-hemolysine

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients having implant infection due to S. aureus treated by DAIR managed at the Lyon Bone and joint infection reference Center between 2006 and 2018

You may qualify if:

• patients having implant infection due to S. aureus treated by DAIR

You may not qualify if:

• none

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Hospices Civils de Lyon

Lyon, 69004, France

RECRUITING

MeSH Terms

Conditions

Staphylococcal Infections; Persistent Infection

Interventions

delta hemolysin protein, Staphylococcus aureus

Condition Hierarchy (Ancestors)

Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• FLORENT VALOUR, Md,PhD

  Hospices Civils de Lyon

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Johanna Boulant, CRA

CONTACT

johanna.boulant@chu-lyon.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: clinical research assistant

Study Record Dates

• First Submitted: January 4, 2019
• First Posted: January 8, 2019
• Study Start: January 1, 2018
• Primary Completion: December 31, 2018
• Study Completion: December 31, 2023
• Last Updated: April 13, 2023

Record last verified: 2023-04

Locations

FR (1)